Objective: Primary aldosteronism (PA) is characterized by hypertension, hypokalemia and suppressed renin-angiotensin system caused by autonomous aldosterone production. The aim of this study was to localize mRNA expression of the genes coding for steroidogenic enzymes in adrenals from a group of patients with PA and relate this to clinical work-up, histopathology and outcome of adrenalectomy.
Introduction
Several forms of primary aldosteronism (PA) have been reported since Conn's description of the syndrome in 1955 (1) . Clinical features of the classical syndrome are autonomous production of aldosterone, suppressed renin activity, hypokalemia and hypertension. The two major forms are unilateral aldosterone-producing adenoma (APA) and bilateral adrenal hyperplasia (BAH), but hereditary varieties, such as familial hyperaldosteronism type I (FH I; glucocorticoid-remediable hyperaldosteronism) (2, 3) and type II (FH II) with hyperaldosteronism not suppressible by glucocorticoids (4) , have also been found.
The steroid synthesis from cholesterol to aldosterone and cortisol in normal adrenal cortex comprises several enzymatic steps. The enzymes required for the final steps of aldosterone synthesis are 11b-hydroxylase, 18-hydroxylase and 18-oxidase, which are encoded by a single gene CYP11B2 (5), while for cortisol production 17a-hydroxylase and 11b-hydroxylase, coded for by the genes CYP17 (6 -8) and CYP11B1 (5), are needed. Aldosterone is synthesized only in the zona glomerulosa, whereas cortisol is produced in the zonae fasciculata and reticularis.
Patients with APA may be cured by unilateral adrenalectomy, while medical therapy with mineralocorticoid antagonists is recommended for patients with BAH.
In spite of thorough clinical work-up and subsequent careful histopathology, it may sometimes be difficult to differentiate between adenoma and hyperplasia.
To facilitate differentiation of subtypes of adrenocortical adenomas, we have previously applied mRNA in situ hybridization on paraffin-embedded specimens (9) , characterizing and localizing the expression of genes for different steroidogenic enzymes. In the present study, the aim was to localize mRNA expression of the genes coding for steroidogenic enzymes in adrenals from a group of PA patients and correlate the findings to clinical data, histopathology and outcome of adrenalectomy.
Subjects and methods

Subjects
Thirty-seven patients underwent adrenalectomy for PA at the Karolinska Hospital from 1987 to 2001. Subjects whose complete clinical data or tissue was lacking, altogether 10 patients, were excluded from the study. The remaining 27 patients comprised 14 women (aged 16 -79 years, mean 45 years) and 13 men (aged 42 -75 years, mean 54 years). They all had hypertension and hypokalemia ( Table 1) .
The preoperative endocrinologic evaluations were carried out with the normokalemic patients receiving potassium supplementation and normal sodium intake. Serum sodium concentrations and urinary sodium excretion were checked. Plasma renin activity was measured on samples drawn during recumbency and after 2-4 h in the upright position. All patients had elevated urinary aldosterone excretion, and suppressed plasma renin activity. Thus, the diagnosis of PA was ascertained.
All 27 patients were examined by computed tomography (CT). The adrenal masses seen on CT had a variation of 0.8-3 cm in diameter except in patient 24 (5.5 cm). Four adrenals had normal appearance (patients 1, 3, 6 and 17). Twenty patients were subsequently examined by 131 I-cholesterol scintigraphy with dexamethasone suppression (10) . Nine patients were examined by adrenal venous sampling (AVS) to determine the aldosterone/cortisol ratio on the right and left sides (11) . The results indicated that the origin of excess aldosterone secretion was the left adrenal in 20 and the right in seven patients. Patients were operated by the open or laparoscopic approach, and unilateral adrenalectomy was performed.
At histopathologic evaluation, an adenoma was defined as a solitary dominant cortical nodule with a capsule or a well-demarcated border to the surrounding tissue. Hyperplasia was diagnosed when a homogeneous thickening of the zona glomerulosa with or without multiple smaller or larger nodules was present (12) . The histopathologic diagnoses of the adrenals were as follows: adenoma, 11; hyperplasia, one; and adenoma and/or hyperplasia, 15 (Table 1) -that is, even after histopathologic re-evaluation, it was difficult to decide whether the nodule was an adenoma or part of a nodular hyperplasia.
Normal adrenal control
Adrenals removed during operation for renal carcinoma from five patients were included as controls (Fig. 1) . These patients had no medication for hypertension.
Ethics
The local committee for medical ethics approved the present study.
Methods
Data collection and follow-up
Clinical data were collected, and an additional followup including blood pressure, medication and measurement of sodium, potassium, aldosterone and renin was performed. Cure of PA was defined as normalization of aldosterone, renin and potassium.
mRNA in situ hybridization
After adrenalectomy, adrenals were chilled with ice and cut in slices for photography to document macroscopic appearance. Selected tissue specimens, that is, dominant nodule and the remaining cortex, were then fixed in 4% phosphate-buffered formaldehyde and routinely embedded in paraffin. The in situ hybridization was performed essentially as described previously (9) .
Probe preparation Oligonucleotide probes with sequences complementary to mRNAs encoding for the synthesizing enzymes 11b-hydroxylase (CYP11B1, nucleotides 548-582; GenBank/EMBL Data Bank accession no. M32879), 18-hydroxylase (CYP11B2, nucleotides 477 -511; GenBank/EMBL Data Bank accession no. M32881), 17a-hydroxylase (CYP17A, nucleotides 8290-8329; GenBank/EMBL Data Bank accession no. M63871) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, nucleotides 1149 -1193, GenBank/EMBL Data Bank accession no. M33197) (13) were synthesized (Genset, Paris, France). The entire gene sequences for CYP11B1 and CYP11B2 are 95% identical in coding regions (5) . Thus, the oligonucleotide sequences were carefully chosen to avoid cross-reactivity of the probes. The probes generated were approximately 67% identical. Probe specificity control for CYP11B2 and CYP11B1 was made previously (9) . The GAPDH probe was used to ascertain the presence of tissue mRNA. In addition, a sense probe identical with a sequence of the 17a-hydroxylase gene was synthesized and used as a negative control. The oligonucleotides were 3 0 -end-labeled with a 35 S-poly A tail, using terminal deoxynucleotidyl transferase (TdT, Amersham Pharmacia Biotech Europe GmbH, Freiburg, Germany). A mixture of 2.9 ml TdT-5x-buffer, 1 ml template (40 ng), 8.5 ml 35 S-dATP (12.5 mCi/ml, Perkin Elmer Life Sciences, Zaventem, Belgium) and 2 ml TdT (14 U/ml, Amersham Pharmacia Biotech Europe GmbH), was incubated for 12 h at 37 8C. Probes were purified using QIAquick Nucleotide Removal Kit (Qiagen GmbH, Hillden, Germany) according to the manufacturer's recommendations, and the terminal step, elution of DNA, used 130 ml buffer. This generated probes to a specific activity of 2.7 -6.3 £ 10 5 c.p.m./ml. An addition of 1.5 ml 2 M dithiotreitol (DTT, Sigma Chemical Co, St Louis, MO, USA) was made to protect the sulfur of the labeled probe from oxidation.
In situ hybridization To prevent contamination by RNases, all solutions before and during hybridization were treated with 0.1% diethylpyrocarbonate (Sigma) and autoclaved, and glassware was baked at 120 8C overnight. Paraffin-embedded tissue specimens were cut in sections of 5 mm and mounted on Super Frost Plus slides (Menzel-Gläser, Braunschweig, Germany). The sections were deparaffinized with Lemonene (BioClear, Bio-Optica, Milan, Italy), rehydrated through graded ethanol and treated with Proteinase K (Sigma) 1 mg/ml in phosphate-buffered saline (PBS) for 30 min at 37 8C. Slides were then acetylated in 0.1 M triethanolamine (Riedel-de Haen, Seelze, Germany) buffer, pH 8.0, containing 0.25% acetic anhydride (Sigma) for 10 min at room temperature, washed in 2 £ SSC (1 £ SCC: 150 mM sodium cloride, 15 mM sodium citrate, pH 7.0), dehydrated through graded ethanol solutions and air dried. Prior to hybridization, the sections were heated to 60 8C for 30 min.
Hybridization solution, containing 50% deionized formamide (Sigma), 2 £ SSC, 20 mM Tris -HCl, pH 8.0, Denhart's solution (0.02% Ficoll (Sigma), 0.02% polyvinylpyrrolidone (Sigma), 0.02% bovine serum albumin fraction V (Sigma)), 1 mM EDTA (Sigma), 10% dextran sulfate (average molecular weight 500 kDa, Sigma), and 500 mg/ml RNA type VI from torula yeast (Sigma), was mixed with 500 mg/ml denatured salmon sperm DNA (Sigma) (preboiled, 10 min in water bath and directly transferred to ice to cool to room temperature), 100 mM DTT (Sigma) and 5 or 10 ng/ml 35 S-probe. The mixture was preheated at 42 8C for 30 min, spread on top of the sections covered with Parafilm (American National Can, Neenah, WI, USA) and put in a humidified chamber at 42 8C overnight. The slides were rinsed in 1 £ SSC with 10 mM DTT twice for 15 min at room temperature, in 1 £ SSC three times for 30 min at 60 8C, in autoclaved distilled water, dehydrated through graded ethanol solutions and air dried before autoradiography. The slides were exposed for 3 days to autoradiographic film from Kodak Bio Max MR (Amersham), developed with Kodak developer RP X-Omat EX (Kodak-Industrie, Chalon, France) and fixed with Kodak fixer RP X-Omat LO (Kodak-Industrie). After film exposure, the slides were dipped in autoradiographic emulsion (type NTB2, Eastman Kodak) and exposed for 4 -10 weeks at 4 8C. The slides were developed with D19 (KodakPathe, Paris, France), fixed with sodium fixer (KodakPathe) and counterstained with hematoxylin and eosin.
Microscopic semiquantitative estimation
Microscopic semiquantitative estimation of the mRNA expression ( Table 2 ) was made in both light-and dark-field microscopes. Assessment was made of the number of silver grains on the cells and the number of cells with mRNA expression.
Estimation of cellular composition
Cellular composition was estimated according to the cellular differentiation of aldosterone-producing adrenal adenoma, established by Neville and Symington (14) , and divided into two groups: 1) compact cells (CC) having compact cytoplasm including zona glomerulosa-and zona reticularis-like cells as well as hybrid cells; and 2) lipid-rich cells (LC) having large lipidrich cytoplasm resembling zona fasciculata (Table 2) .
Densitometric quantification
Quantification of the autoradiographic film (Figs 2-6 ) was done by microdensitometry, as previously described (15) . In brief, a Macintosh Quadra 700 computer and a CCD camera were used to digitalize frames. Analysis was performed on a Macintosh Performa 6400 computer using the public domain NIH Image program (developed at the US National Institutes of Health: http://rsb. info.nih.gov/nih-image/). Defined areas were measured and obvious artifacts excluded. Measurements represent the mean value of two sections. All measurements were subtracted for film background.
Controls of in situ hybridization technique
No specific binding was seen in any specimen with the sense probe. All specimens had a positive mRNA expression of GAPDH. In addition, the cortical remnant of all specimens showed clear expression of CYP11B1 and CYP17 in the zonae fasciculata and reticularis.
Results
Adrenocortical nodules
Nodules of various sizes are common in human adrenals. The histopathologic differentiation between adenoma and nodules is often difficult. For the evaluation of the in situ hybridization in this study, we instead used dominant nodules (including adenoma) and small nodules. The dominant nodules were morphologically homogeneous or heterogeneous. The homogeneous adrenal nodules (e.g. Fig. 2, patient 17) were composed almost exclusively of zona glomerulosa-like compact cells (CC) ( Table 2 ). The heterogeneous nodules (e.g. Fig. 3, patient 22) had, in addition to CC, a varying extent of large, lipid-rich, zona fasciculata-like cells (LC). The small nodules (e.g. mRNA expression of the genes CYP11B2, CYP11B1 and CYP17
Normal adrenal controls All five normal adrenal controls had expression of the CYP11B2 gene ( Table 2 , Fig. 1 ), but no CYP11B1 or CYP17 expression in the zona glomerulosa. One of the controls had a nodule of 1 mm in diameter showing CYP11B2 expression (not shown). In addition, all normal adrenal controls had a moderate to high expression of CYP11B1 and CYP17 (Fig. 1) in the zonae fasciculata and reticularis.
Adenoma The histopathologic diagnosis was adenoma in 11 patients (patients 1-11). Four of these (patients 1 -4) had CYP11B2 gene expression in a dominant (. 5 mm) nodule only ( Table 2 ). The adrenals from six patients (patients 5-10) showed expression of CYP11B2 also in the zona glomerulosa and/or small (, 5 mm) nodules. One patient (patient 11) lacked adrenal expression of CYP11B2. All patients were considered cured of PA. Patient 8 was cured initially and at Table 1 ) follow-up after 1 year, but the condition had recurred at the latest follow-up 4.5 years after adrenalectomy. In addition, the adrenal from this patient showed highly abundant expression of CYP11B2 in the zona glomerulosa.
Adenoma and/or hyperplasia In 15 patients (patients 12 -26), it was difficult to decide whether a dominant nodule was an adenoma or part of a multinodular hyperplasia. Of these patients, four (patients 12 -15) had CYP11B2 expression in a dominant nodule only, while eight (patients 16 -23) had additional expression in small nodules and/or zona glomerulosa. Also in this group, one adrenal (patient 26) lacked CYP11B2 expression. All these patients were considered cured of PA. Two patients (patient 24, Fig. 4 ; patient 25, Figs 5 and 6) lacked CYP11B2 expression in the dominant nodule but had expression of CYP11B1 and CYP17. One of these patients (patient 24, Fig. 4 ), who had a large dominant nodule (5.5 cm), had one 3 mm nodule and some smaller nodules with CYP11B2, but not CYP11B1 or CYP17, expression. Postoperatively, PA persisted, and antihypertensive therapy was still needed to control blood pressure. Moreover, the adrenal removed at the first operation of the other patient (patient 25, Fig. 5 ) contained, in addition to the dominant nodule, a small nodule that showed CYP11B2, but not CYP11B1 or CYP17, expression. This patient remained hypertensive with elevated aldosterone and low serum potassium level (Table 1) , postoperatively, and did not tolerate antihypertensive medication. The second operation revealed an adrenal with hyperplasia ( Fig. 6) , comprising several small nodules with CYP11B2 and very low CYP11B1 and CYP17 gene expression. Hypertension persisted but was easier to control, and the patient had no signs of hyperaldosteronism during 11 years of follow-up after the second operation.
Hyperplasia Patient 27 had the diagnosis of cortical hyperplasia, and no CYP11B2 expression could be found in the adrenal, but there was expression of CYP11B1 and CYP17. This patient was initially cured of PA and remained so after 3.5 years, but the condition had recurred at the latest follow-up 4.5 years after adrenalectomy.
All adrenals
The dominant nodules of all adrenals showed varying expression of CYP11B1 and CYP17 (Table 2) , and the zonae fasciculata and reticularis had moderate to high expression.
Clinical outcome Twenty-three patients were considered cured of PA by unilateral adrenalectomy. Of them, 11 patients (48%) were receiving no hypertensive medication at the latest follow-up.
Discussion
We have previously found a correlation between expression of the CYP11B2 gene and in vitro release of aldosterone from adenomas removed due to PA (9) . Thus, it may be assumed that the mRNA expression of CYP11B2 indicates aldosterone production in these cells. Furthermore, a correlation between expression of CYP17 and release of cortisol, and a positive correlation between CYP11B1 and CYP17 expression were found, indicating that CYP11B1 and CYP17 expression reflects cortisol production.
In the present study, as expected, expression of the aldosterone-producing enzyme CYP11B2 gene was seen in the zona glomerulosa in all five normal adrenal controls. However, two normal adrenals had very low CYP11B2 expression. This could be due to sparse presence of mRNA (16) , possibly related to extra-adrenal reasons, such as high sodium intake or the sensitivity level of the in situ hybridization technique. One adrenal also exhibited a small nodule with CYP11B2 expression, which may represent a normal variant or early development of PA. High expression of the genes coding for cortisol-producing enzymes, CYP11B1 and CYP17, was seen in the zonae fasciculata and reticularis, but not in the zona glomerulosa, as previously shown (17) . In a recent study (16) , mRNA expression of CYP11B2, CYP11B1 and CYP17 was demonstrated by a real-time RT-PCR assay in normal adrenal cortex and aldosterone-producing adenoma. These authors found an almost 10-fold difference in CYP11B2 expression between APA and normal tissue. We noted a similar difference in our study, although the scarce expression of CYP11B2 could not be measured in normal adrenals with the densitometric method. However, it was seen on the film and in the microscope. In agreement with the study just cited (16) , in situ hybridization has also demonstrated expression of CYP11B1 and CYP17 in APA (9) .
The differential diagnosis between PA due to a solitary dominant aldosterone-producing adrenal nodule (adenoma) and adrenocortical nodular hyperplasia can be difficult. The renin-angiotensin axis in adenoma is usually suppressed, and adrenocorticotropic hormone (ACTH) partially regulates aldosterone secretion, while in bilateral hyperplasia the sensitivity to the reninangiotensin system is preserved. However, a subset of APAs is renin sensitive, and unilateral hyperplasia is also recognized (18) . Furthermore, adrenocortical nodules without hyperfunction are common in the adrenal and can coexist with PA. Adrenal incidentalomas are found by CT or magnetic resonance imaging (MRI) during diagnostic work-up for nonadrenal causes in 2-10% of cases (19, 20) . These incidentalomas are often nonhyperfunctioning adrenocortical adenomas (21) . Thus, it is of value to identify where in the adrenal the aldosterone production is localized.
By definition, the cured patients had normal renin, aldosterone and potassium levels on follow-up. Eleven patients (48%) had no antihypertensive medication. Other studies report a cure rate of hypertension of 41 -71% in patients operated for PA (22 -24) .
The 22 patients (patients 1-10, and 12 -23) with CYP11B2 expression in a dominant nodule were cured of PA. They probably all had a unilateral APA. However, one of these patients (patient 8), who also had high CYP11B2 expression in the zona glomerulosa, as well as the patient with hyperplasia (patient 27), was initially cured, but the condition later recurred, indicating bilateral disease.
In two patients (patients 11 and 26) apparently cured by unilateral adrenalectomy from PA at followup, no CYP11B2 expression could be visualized. This is difficult to explain, but it may be due to lack of representative tissue or insufficient sensitivity of the method. Theoretically, the CYP11B1 protein may acquire the capacity to produce aldosterone by mutation to CYP11B2-like sequences in regions encoded by exons 5 and 6 (25). It does not seem likely, however, that such somatic mutations would confer any growth advantage on the cells. Therefore, the presence of a mutated CYP11B1 gene in the hyperplastic regions of the adrenal cortex seems unlikely.
Two patients (patients [24] [25] showed CYP11B2 expression in small nodules and the zona glomerulosa, but not in the dominant nodule. The small nodules were most likely responsible for increased aldosterone production, while the dominant nodule presumably represented a nodule without hyperfunction. These patients were not cured, probably due to autonomous aldosterone production also in the remaining adrenal. One of these patients (no. 25) had his second adrenal removed and was then cured of PA, but he was still hypertensive. The final diagnosis in these two patients was concluded to be aldosterone-producing bilateral nodular hyperplasia.
Two-thirds of the adrenals with CYP11B2 expression in a dominant nodule in this study also had expression in the zona glomerulosa and/or small nodules. These results suggest that the aldosterone production does not effectively suppress CYP11B2 expression in the normal cortex, at least not in all PA patients. In the nodules with CYP11B1 expression, there may be an increased production of corticosterone by 11b-hydroxylase activity, possibly stimulating aldosterone synthesis, although the rate-limiting step for aldosterone synthesis is considered to be the 18-oxidase activity of CYP11B2 gene.
The present study demonstrates for the first time a relationship between in situ hybridization expression of CYP11B2 and CYP11B1 and the outcome of adrenalectomy in a clinically well-controlled group of patients operated for PA. The results illustrate the value of knowing which part of the adrenal cortex is producing aldosterone for correct subclassification of PA. mRNA in situ hybridization can visualize the location of the probable steroid production, unlike the currently used histopathologic evaluation. Clinical data, endocrinologic evaluation and histopathology, in combination with mRNA in situ hybridization of steroidogenic enzyme genes, provide improved means for correct subclassification postoperatively of patients with PA.
The in situ hybridization method is too complicated for regular use in histopathology and needs further development for routine use. At present, the method is of special value for analysis of cases not cured by adrenalectomy.
